(openPR) - Berlin, Germany, August 20, 2008. ATLAS Biolabs GmbH has expanded its biochip-based services to include the Agilent technology platform. Thus, ATLAS Biolabs GmbH now also offers a third of the world’s three leading microarray technologies, in addition to Affymetrix and Illumina. Agilent’s chip technology is characterized by multiplex formats, high accuracy and reproducibility, as well as a high measure of flexibility. Production of customized chips thus becomes cheaper and faster. The catalogue arrays include multiplex formats for humans, mice, rats, Arabidopsis, Drosophila, yeasts, and various other model organisms. The services at ATLAS Biolabs also include chip design in custom array formats and a detailed biomathematical analysis of the expression data.
Media inquiries
Dr. Holger Bengs
Biotech Consulting
Germany
phone: +49 (0)69 619 94 273
email : info@holgerbengs.de
About ATLAS Biolabs:
ATLAS Biolabs GmbH is a spin-off of the RZPD Deutsches Ressourcenzentrum für Genomforschung GmbH (German Resource Centre for Genome Research) and the University of Cologne, Germany. ATLAS Biolabs specializes in such chip-based molecular genetic services as gene expression analyses, SNP gene typing, and CGH analyses. Among the company’s customers are many academic research institutions, industrial companies in the pharmaceutical or biotechnology sector as well as practicing doctors.
About chip-based gene expression analyses:
Chip-based gene expression analyses can analyse the activity of tens of thousands of genes in parallel, and thus contribute immensely to the understanding of complex genetic networks. Through the systematic analysis of complete chromosomes or even genomes, it has been possible in many cases to discover hitherto unknown transcription activities. However, DNA chips for gene expression analysis are not only useful in basic research. Increasingly, they play an important role in clinical research and even in routine diagnostics. To cite just one example: so-called gene signatures can predict the further development of tumours with a high degree of probability.
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
Newsfeed
